The Valley Desk

Clinical trial reportArthritis & rheumatology (Hoboken, N.J.)Published

Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

12 of 32 authors shown in byline order.

Read the publication ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, University of Pennsylvania. Affiliation source

Publication record

Type
Clinical trial report
Venue
Arthritis & rheumatology (Hoboken, N.J.)
Published
Subject terms
Skin; Humans; Scleroderma, Systemic; Scleroderma, Diffuse; Treatment Outcome; Severity of Illness Index; Cannabinoid Receptor Agonists; Dronabinol
PubMed ID
37098795
Added to directory
Source checked

Report a correction or request removal